Skip to content
10-K

Annual Report

Nugenerex Immuno-oncology, Inc.

0001607062-20-000307

← back to feed
Filed
Oct 29, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2020 · Oct 28, 2020 400.3M sh
Stockholders Equity FY 2020 · Jul 31, 2020 −$5.84M
Stockholders Equity FY 2020 · Jul 31, 2019 −$4.38M
Stockholders Equity FY 2020 · Jul 31, 2018 −$3.66M
Current Liabilities FY 2020 · Jul 31, 2020 $5.84M
Current Liabilities FY 2020 · Jul 31, 2019 $4.38M
Total Assets FY 2020 · Jul 31, 2020 $84
Total Assets FY 2020 · Jul 31, 2019 $389
Sga Expense FY 2020 · Jul 31, 2020 $336.3K
Sga Expense FY 2020 · Jul 31, 2019 $38.74K
Rd Expense FY 2020 · Jul 31, 2020 $397.32K
Rd Expense FY 2020 · Jul 31, 2019 $354K
Net Income FY 2020 · Jul 31, 2020 −$1.52M
Net Income FY 2020 · Jul 31, 2019 −$1.11M
Operating Income FY 2020 · Jul 31, 2020 −$733.61K
Operating Income FY 2020 · Jul 31, 2019 −$392.74K